About
Greg, a biopharma leader for more than 20 years, has been personally affected by epilepsy. After years of absence seizures, which often precede epilepsy, his son Conner was diagnosed with epilepsy in 2014. Greg is dedicated to leveraging his drug development experience and working with key opinion leaders (KOLs) to identify new therapeutic options for patients affected by epilepsy. He, along with his team of KOLs, believe they have finally found that option with Staccato Alprazolam. Prior to founding Engage Therapeutics, Greg played an integral role in the growth of Advaxis Immunotherapies, a Princeton, N.J., based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its Chief Operating Officer, he was instrumental in helping to secure more than $200 million in funding and in identifying and negotiating partnerships with companies such as Amgen, AstraZeneca and Merck & Co., Inc. Greg also
Position in the VCSift Database
- • 5 investors hold the President, CEO & Founder role in VCSift. Greg Mayes is one of them.
- • 26 investors are based in Summit, New Jersey, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Summit, US
Contact Information
Find more investors like Greg
Search Investors